AG10-501 ACT-EARLY | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase N/A

1 Location

Brief description of study

The AG10-501 ACT-EARLY study is a randomized, multicenter, double-blind, placebo-controlled study of acoramidis for prevention of ATTR. The objective of this study is to evaluate if the use of acoramidis as a prophylactic intervention in individuals who are carriers of a known pathogenic TTR variant but with no clinical evidence of ATTR could delay the onset of disease or prevent it entirely .Participants will be randomized ito acoramidis 712 mg orally BID or to a matching placebo.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

TBD

Updated on 21 Jul 2025. Study ID: 25-0199

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Please provide your preferred way of contact

Other language

By Submitting your information, you agree that your details may be shared with the selected study site and handled in accordance with this Website's Privacy Policy (see link in footer). You may be contacted by email, text message, or phone regarding this study and other research opportunities that may be of interested to you. You can unsubscribe from these communications at any time. Message and data rates may apply.

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center